AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
AbCellera (Nasdaq: ABCL) will report its full year 2021 financial results on February 24, 2022, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
The live webcast of the earnings conference will be available through a link that will be posted on AbCellera’s Investor Relations website. A replay of the webcast will be available through the same link following the conference call.
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. To learn more, visit www.abcellera.com.
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220126005945/en/
Media:
Investor Relations:
Source: AbCellera